XOMAHealthcare · BiotechnologyXOMA Stock Forecast: XOMA Royalty Corp. Price Predictions for 2026-2027
The 2 Wall Street analysts covering XOMA Royalty Corp. hold a median 12-month price target of $39 — -2.9% from the last close.
XOMA stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores XOMA Royalty Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
We don’t hold a current model rank for this company.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
XOMA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on XOMA, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
The green dot is the last close — the median target sits −2.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 Apr 2026 | HC Wainwright & Co. | Downgrade | Neutral | $39 |
| 20 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 Feb 2026 | Leerink Partners | Maintains | Outperform | — |
| 11 Dec 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 Dec 2025 | Leerink Partners | Maintains | Outperform | — |
| 9 Dec 2025 | LUCID CAPITAL MARKETS | Initiates | Buy | — |
| 28 May 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 Apr 2025 | Benchmark | Initiates | Buy | — |
| 28 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Feb 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Dec 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 2 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 23 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Aug 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 9 July 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 31 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. XOMA appears on the weeks it earns a place.
XOMA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
XOMA Royalty Corp. (XOMA) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 25.6×
- Price / sales
- 14.6×
- Price / book
- 5.2×
- EV / EBITDA
- 67.8×
Cheaper than 31% of US stocks
Cheaper than 11% of US stocks
Cheaper than 21% of US stocks
Cheaper than 3% of US stocks
- Revenue growth (YoY)
- −22.6%
- Earnings growth (YoY)
- 88.6%
- Gross margin
- —
- Operating margin
- −3.9%
- Net margin
- 69.6%
Higher than 10% of US stocks
Higher than 83% of US stocks
Higher than 28% of US stocks
Higher than 98% of US stocks
- Return on equity
- 34.2%
- Return on assets
- 1.3%
- Dividend yield
- 5.4%
Higher than 89% of US stocks
Higher than 53% of US stocks
Higher than 84% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
XOMA vs competitors
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| XOMAXOMA Royalty Corp. | $710.2M | — |
| LLYEli Lilly & Co.* | $1.2T | 91 |
| JNJJohnson & Johnson* | $650.8B | 92 |
| ABBVAbbVie, Inc.* | $468.1B | 96 |
| MRKMerck & Co., Inc.* | $378.6B | 83 |
| UNHUnitedHealth Group, Inc.* | $353.4B | 75 |
| AMGNAmgen, Inc.* | $236.8B | 92 |
* Nearest Healthcare names by size — few biotechnology companies of this scale trade in the US universe.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own XOMA Royalty Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about XOMA stock
What is the XOMA stock price forecast for 2026-2027?
The 2 Wall Street analysts covering XOMA Royalty Corp. have a median 12-month price target of $39, with estimates ranging from $39 to $39. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is XOMA stock a buy right now?
Of the 2 analysts covering XOMA Royalty Corp., 0 rate it a Buy, 2 a Hold and 0 a Sell. None of this is personal advice — it does not consider your circumstances.
Will XOMA stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts implies -2.9% from the last close. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the XOMA stock forecast for 2030?
No analyst covering XOMA Royalty Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XOMA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $39 to $39 over the next 12 months.
What does XOMA Royalty Corp. do?
XOMA Corporation operates as a biotech royalty aggregator, acquiring economic rights to future milestone and royalty payments from pre-commercial clinical candidates and commercial therapies licensed to pharmaceutical and biotechnology companies. This model provides sellers with non-dilutive, non-recourse funding to advance drug development or for general corporate purposes, while XOMA Royalty builds a diversified portfolio spanning multiple therapeutic areas and development stages.
About XOMA Royalty Corp.
XOMA Corporation operates as a biotech royalty aggregator, acquiring economic rights to future milestone and royalty payments from pre-commercial clinical candidates and commercial therapies licensed to pharmaceutical and biotechnology companies. This model provides sellers with non-dilutive, non-recourse funding to advance drug development or for general corporate purposes, while XOMA Royalty builds a diversified portfolio spanning multiple therapeutic areas and development stages. The company focuses on development-stage assets with significant commercial potential, partnered with well-capitalized entities, including royalties on marketed products and clinical programs. XOMA Corporation also engages in transactions with distressed biotechs, acquiring and monetizing their intellectual property to generate returns. With over 120 assets, it plays a key role in the biotech financing ecosystem by bridging funding gaps and supporting innovation in human health therapies across regions including the United States, Europe, and Asia Pacific. Founded in 1981 and headquartered in Emeryville, California, XOMA Corporation maintains a lean operation dedicated to royalty aggregation.
CEO Mr. Owen P. Hughes Jr. · 14 employees · United States · https://www.xoma.com